phosphatidylcholines has been researched along with ciprofloxacin in 11 studies
| Studies (phosphatidylcholines) | Trials (phosphatidylcholines) | Recent Studies (post-2010) (phosphatidylcholines) | Studies (ciprofloxacin) | Trials (ciprofloxacin) | Recent Studies (post-2010) (ciprofloxacin) |
|---|---|---|---|---|---|
| 32,204 | 443 | 5,593 | 16,060 | 1,331 | 6,092 |
| Protein | Taxonomy | phosphatidylcholines (IC50) | ciprofloxacin (IC50) |
|---|---|---|---|
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA gyrase subunit B | Bacillus subtilis subsp. subtilis str. 168 | 6.3 | |
| DNA gyrase subunit A | Bacillus subtilis subsp. subtilis str. 168 | 6.3 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.31 | |
| DNA gyrase subunit B | Staphylococcus aureus | 4.32 | |
| DNA gyrase subunit A | Escherichia coli K-12 | 0.6845 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.5632 | |
| DNA topoisomerase 4 subunit B | Staphylococcus aureus | 6.485 | |
| DNA topoisomerase 4 subunit A | Staphylococcus aureus | 4.8011 | |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA gyrase subunit A | Staphylococcus aureus | 4.32 | |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA topoisomerase 4 subunit A | Bacillus subtilis subsp. subtilis str. 168 | 1.7 | |
| DNA topoisomerase 4 subunit B | Bacillus subtilis subsp. subtilis str. 168 | 1.7 | |
| GABA theta subunit | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | 0.41 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bedard, J; Bryan, LE | 1 |
| Cullis, PR; Fenske, DB; Maurer, N; Maurer-Spurej, E; Wong, KF | 1 |
| Chang, TM; Wong, JP; Yu, WP | 1 |
| Desai, TR; Finlay, WH; Hancock, RE | 1 |
| Domènech, O; Hernández-Borrell, J; Merino, S; Montero, MT; Ruiz, N; Viñas, M | 1 |
| Chono, S; Morimoto, K; Seki, T; Tanino, T | 1 |
| Cullis, PR; Edwards, K; Johnston, MJ; Karlsson, G | 1 |
| Hosny, KM | 1 |
| Al-Mahallawi, AM; Khowessah, OM; Shoukri, RA | 1 |
| Aljuffali, IA; Chen, CH; Fang, JY; Hsu, CY; Hu, KY; Sung, CT | 1 |
| Chai, G; Li, J; Lin, Y; Ling, J; Shetty, N; Wang, S; Wickremasinghe, H; Yu, HH; Yu, S; Zhou, QT; Zou, P | 1 |
11 other study(ies) available for phosphatidylcholines and ciprofloxacin
| Article | Year |
|---|---|
Interaction of the fluoroquinolone antimicrobial agents ciprofloxacin and enoxacin with liposomes.
Topics: Anti-Infective Agents; Chemical Phenomena; Chemistry, Physical; Ciprofloxacin; Enoxacin; Hydrogen-Ion Concentration; Liposomes; Membranes, Artificial; Phosphatidylcholines; Phospholipids; Solubility | 1989 |
Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients.
Topics: Amines; Ammonium Sulfate; Ciprofloxacin; Doxorubicin; Drug Carriers; Epirubicin; Hydrogen-Ion Concentration; Liposomes; Pharmaceutical Preparations; Phosphatidylcholines; Phosphatidylglycerols; Solubility; Vincristine | 1999 |
Biodegradable polylactic acid nanocapsules containing ciprofloxacin: preparation and characterization.
Topics: Biodegradation, Environmental; Buffers; Capsules; Chemistry, Pharmaceutical; Ciprofloxacin; Delayed-Action Preparations; Drug Stability; Lactic Acid; Particle Size; Phosphatidylcholines; Polyesters; Polymers; Solubility; Time Factors | 1999 |
A facile method of delivery of liposomes by nebulization.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Adrenergic beta-Agonists; Aerosols; Albuterol; Amino Acid Sequence; Anti-Infective Agents; Chemical Phenomena; Chemistry, Physical; Ciprofloxacin; Dimyristoylphosphatidylcholine; Liposomes; Molecular Sequence Data; Particle Size; Phosphatidylcholines; Phosphatidylglycerols; Powders | 2002 |
Preliminary studies of the 2D crystallization of Omp1 of Serratia marcescens: observation by atomic force microscopy in native membranes environment and reconstituted in proteolipid sheets.
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; Ciprofloxacin; Crystallization; Dimyristoylphosphatidylcholine; Escherichia coli; Indicators and Reagents; Lipid Bilayers; Membranes; Microscopy, Atomic Force; Phosphatidylcholines; Porins; Proteolipids; Serratia marcescens | 2004 |
Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes.
Topics: Administration, Intranasal; Animals; Anti-Infective Agents; Cholesterol; Ciprofloxacin; Drug Delivery Systems; Glycine max; L-Lactate Dehydrogenase; Liposomes; Lung; Macrophages, Alveolar; Male; Microbial Sensitivity Tests; Organophosphates; Particle Size; Phosphatidylcholines; Rats; Rats, Sprague-Dawley; Time Factors | 2006 |
Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations.
Topics: Anti-Infective Agents; Antibiotics, Antineoplastic; Cholesterol; Ciprofloxacin; Delayed-Action Preparations; Doxorubicin; Liposomes; Particle Size; Phosphatidylcholines | 2008 |
Ciprofloxacin as ocular liposomal hydrogel.
Topics: Amines; Animals; Biological Availability; Chemistry, Pharmaceutical; Cholesterol; Ciprofloxacin; Eye; Hydrogel, Polyethylene Glycol Dimethacrylate; Liposomes; Phosphatidylcholines; Rabbits | 2010 |
Nano-transfersomal ciprofloxacin loaded vesicles for non-invasive trans-tympanic ototopical delivery: in-vitro optimization, ex-vivo permeation studies, and in-vivo assessment.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Carriers; Drug Stability; Male; Nanoparticles; Permeability; Phosphatidylcholines; Rabbits; Skin; Sodium Cholate; Tympanic Membrane | 2014 |
Intravenous anti-MRSA phosphatiosomes mediate enhanced affinity to pulmonary surfactants for effective treatment of infectious pneumonia.
Topics: Administration, Intravenous; Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Models, Animal; Nanoparticles; Phosphatidylcholines; Pneumonia; Polyethylene Glycols; Pulmonary Surfactants; Rats; Rats, Sprague-Dawley; Staphylococcal Infections | 2018 |
Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.
Topics: A549 Cells; Anti-Infective Agents; Cell Survival; Ciprofloxacin; Colistin; Drug Compounding; Drug Resistance, Bacterial; Drug Synergism; Humans; Phosphatidylcholines; Phospholipids; Pseudomonas aeruginosa; Surface Properties | 2018 |